Immunoassay News and Research

RSS

Plasma ACE2 concentration associated with increased risk of major cardiovascular events

A team of scientists at the Population Health Research Institute, Hamilton Health Sciences, and McMaster University, Hamilton, in Ontario, Canada, revealed that increased plasma ACE2 levels in the blood could indicate a higher risk of major cardiovascular events. The study is published in the journal The Lancet.

6 Oct 2020

Production of six monoclonal antibodies against SARS-CoV-2 spike protein

Youjia Guo et al. in a recent bioRxiv preprint paper demonstrate the robust performance of mouse anti-SARS-CoV-2 spike monoclonal antibodies in immunoassays, including western blotting, ELISA, immunofluorescence, and immunoprecipitation and also neutralizing activity in vitro against SARS-CoV-2 infection.

5 Oct 2020

AbC-19 blood test detects COVID-19 antibodies 20 weeks after first symptoms/PCR positive result

Serological antibody immunoassays are one of the essential tools to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a new study, Immunoglobulin G (IgG) antibodies are detected in a large cohort, lasting up to 140 days. The researchers propose an alternative to reverse transcription-polymerase chain reaction (RT-PCR) positive status as a standard for assessing SARS-CoV-2 antibody assays and show robust performance metrics for the AbC-19 rapid test.

5 Oct 2020

Discovery of high affinity binders for SARS-CoV-2 spike protein

An exciting, 'tour-de-force' paper by researchers from the Massachusetts Institute of Technology describes de novo discovery of high-affinity peptide binders for SARS-CoV-2 spike glycoprotein, which opens the door for the development of rapid viral identification or conjugates for virus-directed delivery of therapeutics.

30 Sep 2020

Siemens’ SARS-CoV-2 antibody immunoassays meet regulatory targets

New research being presented at the ESCMID Conference on Coronavirus Disease (ECCVID, online 23-25 September) shows that, in a head-to-head comparison of five tests used to detect SARS-CoV-2 antibodies (known as 'immunoassays'), an assay manufactured by Siemens and one developed by an academic partnership led by the University of Oxford had the most accurate results.

24 Sep 2020

COVAM assay may help select convalescent plasma units for treatment of acute COVID-19

A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.

21 Sep 2020

SARS-CoV-2 infects monocytes and macrophages, without cytopathic effect

A team of researchers from Aix-Marseille Univ, IHU-Méditerranée Infection, Institut Paoli Calmettes and Laboratoire d’Immunologie, Marseille, France, conducted experiments to determine if SARS-CoV-2 can affect the myeloid compartment or infect monocytes and macrophages.

20 Sep 2020

3D printed nanoparticle biosensing platform detects SARS-CoV-2 antibodies within seconds

Pandemics caused by novel infectious agents like the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Zika, or Ebola virus seriously impact human health and lives while also overwhelming health care systems all over the world. Early detection and diagnosis allow isolation of the infected patients and contact tracing, which can mitigate the spread of the virus and save lives, especially when a significant number of the patients are asymptomatic.

14 Sep 2020

Toyonaka Municipal Hospital reports successful control of COVID-19

Researchers at Toyonaka Municipal Hospital in Japan have shown that the rate of subclinical infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among staff at the hospital is no higher than among the general population in the same area.

14 Sep 2020

New Gyrolab AAVX Titer Kit launched to support the development cell and gene therapies

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® AAVX Titer Kit for adeno-associated virus (AAV) vector titer determination in AAV vector manufacturing.

From Gyros Protein Technologies AB 3 Sep 2020

NIH provides scale-up and manufacturing support for new COVID-19 testing technologies

The National Institutes of Health today announced $129.3 million in scale-up and manufacturing support for a new set of COVID-19 testing technologies as part of its Rapid Acceleration of Diagnostics (RADx) initiative.

2 Sep 2020

Brazilian state of Maranhão heading towards SARS-CoV-2 herd immunity, say researchers

Researchers at the Federal University of Maranhão, Brazil, have conducted a study suggesting that the state of Maranhão is well on its way to acquiring herd immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

2 Sep 2020

Promega introduces new serological antibody test for COVID-19

Promega Corporation today announced the launch of its new serological antibody test for COVID-19 to detect the presence of antibodies against the SARS-CoV-2 virus.

From Promega Corporation 13 Aug 2020

Fujirebio announces launch of clinical testing for new SARS-CoV-2 Antigen assay

Fujirebio Diagnostics, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc, announced today the initiation of clinical testing needed for the submission of its new SARS-CoV-2 Antigen assay for EUA (Emergency Use Authorization) from the U.S. Food and Drug Administration.

6 Aug 2020

NIH invests $248.7 million in new COVID-19 testing technologies to meet U.S. demand

The National Institutes of Health is investing $248.7 million in new technologies to address challenges associated with COVID-19 testing (which detects SARS-CoV-2 coronavirus).

31 Jul 2020

COVID-19 test kits offered by Carolina Liquid Chemistries granted FDA emergency use authorization

Carolina Liquid Chemistries, Corp., an innovative leader in clinical diagnostics and drug screening, is now offering test kits for COVID-19 that have been granted Emergency Use Authorization by the US Food and Drug Administration, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act.

From Carolina Liquid Chemistries Corp. 29 Jul 2020

Inconsistent SARS-CoV-2 antibody results in nephrology workers

Using a broad spectrum of antibody tests the present study revealed inconsistent results for SARS-CoV-2 seroprevalence among asymptomatic individuals, while this was not the case among Covid-19 patients.

29 Jul 2020

UArizona aims to develop a device for quick and accurate detection of pathogens, biological threats

To better protect individuals serving on the front lines of battlefields or dealing with an event like the current COVID-19 health crisis or potential future pandemics, scientists at the University of Arizona College of Medicine - Phoenix are leading an effort to develop a device for easy, quick and accurate detection of pathogens and biological threats.

28 Jul 2020

SphingoTec launches point-of-care test for bio-ADM, a biomarker for life threatening endothelial dysfunction

Diagnostics company SphingoTec GmbH today announced the launch of its IB10 sphingotest® bio-ADM®, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of Bioactive Adrenomedullin. Blood levels of bio-ADM® reflect in real-time the functional status of the endothelium, the inner cell sheet of blood vessels.

24 Jul 2020

SphingoTec introduces a CE-IVD-marked point-of-care test to determine blood levels of bio-ADM

Diagnostics company SphingoTec GmbH today announced the launch of its IB10 sphingotest bio-ADM, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of Bioactive Adrenomedullin (bio-ADM).

22 Jul 2020